Duchenne muscular dystrophy is a recessive X-linked genetic disease caused by dystrophin gene mutations. Cell therapy can be a potential approach aiming to introduce a functional dystrophin in the dystrophic patient myofibers. However, this strategy produced so far limited results. Transforming growth factor-β (TGF-β) is a negative regulator of skeletal muscle development and is responsible for limiting myogenic regeneration. The combination of TGF-β signaling inhibition with myoblast transplantation can be an effective therapeutic approach in dystrophin-deficient patients. Our aim was to verify whether the success of human myoblast transplantation in immunodeficient dystrophic mice is enhanced with losartan, a molecule that downregulates TGF-β expression. In vitro, blocking TGF-β activity with losartan increased proliferation and fusion and decreased apoptosis in human myoblasts. In vivo, human myoblasts were transplanted in mice treated with oral losartan. Immunodetection of human dystrophin in tibialis anterior cross sections 1 month posttransplantation revealed more human dystrophin-positive myofibers in these mice than in nontreated dystrophic mice. Thus, blocking the TGF-β signal with losartan treatment improved the success of myoblast transplantation probably by increasing myoblast proliferation and fusion, decreasing macrophage activation, and changing the expression of myogenic regulator factors.
INTRODUCTION
a model for Duchenne muscular dystrophy (DMD). DMD is caused by mutations in the dystrophin gene, which leads to a severe deficiency of the dystrophin pro-The super family of transforming growth factor-β (TGF-β) cytokines exerts a potent level of control over tein in the muscle. Mutations within the dystrophin gene can either be inherited or occur spontaneously during muscle gene expression. In 1981, Roberts and colleagues (27) reported that TGF-β induced the prolifera-germ line transmission, affecting 1 in 3,500 male births. Dystrophin, the dystrophin-associated glycoprotein com-tion of rat kidney fibroblasts. Since then, TGF-β has been found to have a plethora of effects, such as regula-plex, and laminin α-2 form a link between the intracellular cytoskeleton and the extracellular matrix. This link is tion of cell growth, proliferation, differentiation, adhesion, migration, and apoptosis (21) . Its aberrant expression crucial to maintain the structural integrity of myofibers (5, 25) . The main consequence of dystrophin absence in has been implicated in fibrotic and inflammatory conditions in kidney, liver, and lung (6, 16, 32) . Recently, an skeletal muscle is sarcolemmal instability leading to increased myofiber vulnerability to mechanical stress, in vivo role for TGF-β1 in skeletal muscle regeneration was confirmed (9). Mice deficient for the extracellular resulting in myofiber necrosis, followed by regeneration as long as the regenerative capacity is not annihilated. matrix protein fibrillin-1 have increased TGF-β1 signaling activity that causes failure of skeletal muscle regen-
The frequent cycles of myofiber necrosis and regeneration lead to fibrosis and fat infiltration, which progres-eration (9). These mice are used as a model for the human Marfan syndrome, which is caused by a mutation sively replace the muscle tissue. Cohn et al. (9) found that muscles from mdx mice of the fibrillin-1 gene (11).
There is recent evidence that elevated TGF-β1 signal-expressed elevated levels of proteins induced by TGF-β1 signaling, and also elevated levels of thrombospon-ing also limits regeneration in muscular dystrophies. Cohn et al. (9) investigated this possibility in mdx mice, din-1 (TSP-1), which activates latent TGF-β1 in response 140 FAKHFAKH ET AL.
to signaling through the angiotensin II type 1 receptor Medium was changed every 2 days. At 0, 3, and 6 days, the medium was discarded, and plates were frozen at (AT1). Losartan, an FDA-approved drug, is a potent inhibitor of AT1 activation, thus blocking TGF-β1 acti-−80°C. The day of the assay, plates were thawed and a cell lysis buffer [20 mM Tris, 1 mM dithiothreitol vation by inhibiting TSP-1 production. This blockade restored the regenerative capacity and improved muscle (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% sodium dodecyl sulfate (SDS)] was added to each function in mouse models of Marfan syndrome and DMD (9).
well. The total cellular nucleic acid was measured using florescence at 530 ± 12.5 nm emission following excita-Many older DMD patients are currently being treated with losartan for the presumptive cardiac benefits and tion at 485 ± 10 nm by a Hitachi F-4500 fluorescence spectrophotometer (Hitachi Instruments, Boulder, CO). fibrosis reduction induced by angiotensin II-type 1 receptor blockers. A clinical trial of losartan in children with DMD to evaluate its effects on skeletal muscle Cell Differentiation Assay strength and function was anticipated to begin enroll-Myoblast differentiation was evaluated by counting ment in 2010.
the percentage of nuclei inside myotubes (i.e., syncytia DMD treatment may eventually require a combinawith three or more nuclei). For this test, myoblasts were tion of several therapeutic approaches. Our research cultured in MB-1 for 24 h and the proliferation medium group has recently demonstrated that dystrophin expreswas replaced for 72 h by a fusion medium (Dulbecco's sion following the transplantation of normal myoblasts modified Eagle medium) containing only 2% FBS in protects mdx muscle from contraction-induced damage presence or not of losartan (10 or 100 µM). Myotubes (29) . Moreover, inhibition of myostatin signal, a memwere visualized by myosin heavy chain (MyHC) immuber of TGF-β superfamily, improved the success of nodetection. The cells were fixed with 95% ethanol, transplantation of myoblasts in mdx mice and in immuwashed twice with phosphate-buffered saline (PBS) for nodeficient recombination-activating gene (Rag) −/− /mdx 10 min, and blocked with 10% FBS in PBS for 1 h. The mice (3,12). Thus, in order to verify whether the blocksamples were incubated 2 h at room temperature with a ade of TGF-β1 signal improves the success of myoblast mouse anti-MyHC mAb (MF20, DSHB, Iowa City, IA) transplantation, we have treated Rag −/− /mdx mice with (1:100) and then for 1 h with an anti-mouse Ig Alexa losartan and transplanted normal human myoblasts in 546-conjugated secondary antibody (Invitrogen) diluted their tibialis anterior (TA) muscles.
1:100. Finally, the cells were washed with PBS and mounted with PBS/glycerol. 4′,6-Diamidino-2-phenylin-MATERIALS AND METHODS dole (DAPI) staining was done with PBS to label the Isolation of Human Myoblasts nuclei. The number of nuclei in the myotubes was coun-Primary myoblasts cultures were grown from muscle ted and normalized with the total number of nuclei in biopsies of a human cadaveric donor obtained following the culture well as a measure of terminal differentiation. informed consent of the family and approval by the Human Ethic Committee of the Research Center Hospi-Analysis of Apoptosis and Necrosis tal of Laval University (CRCHUL). The muscle samples An apoptosis and necrosis assay was performed by were dissociated with collagenase and trypsin as preflow cytometry according to the manufacturer's protocol viously described (17) and cultured in MB-1 growth (BD BioSciences, San Jose, CA). Briefly, myoblasts medium (Hyclone, South Logan, UT, USA) with 15% treated or not with losartan (10 µM) were exposed or fetal bovine serum (FBS), 1% penicillin-streptomycin not to 10 mM hydrogen peroxide (H 2 O 2 , Merck Co., (Gibco, Burlington, Ontario, Canada), and 10 ng/ml Inc., NJ) for 2 h. After trypsinization, the cells were basic fibroblast growth factor (Strathmann Biotec AG, harvested, washed twice with Hank's balanced salt solu-Hamburg, Germany) in a humidified atmosphere with tion, and suspended in binding buffer (10 mmol/L 5% CO 2 at 37°C. HEPES, pH 7.4, 140 mmol/L NaCl, 2.5 mmol/L CaCl 2 ).
Cell Proliferation Assay
Aliquots of 100 µl suspension (1 × 10 5 cells) were incubated with 5 µl Annexin V-FITC (fluorescein isothiocy-Cellular growth curves were measured using the CyQuant Cell Proliferation Assay Kit (Invitrogen, Burl-anate) and 5 µl propidium iodide (PI) (50 µg/ml) for 15 min at room temperature in the dark. Binding buffer ington, ON, Canada) according to the manufacturer's instructions. Human myoblasts were seeded in 24-well (400 µl) was added to the cell suspension. The cells were gently vortexed and analyzed within 1 h by flow plates at initial densities of 2 × 10 3 cells/well in a total volume of 100 µl MB-1 supplemented with 10% FBS cytometry (Becton-Dickinson, Oxford, UK). Apoptotic cells were quantified by percentage of Annexin V-FITC-and two concentrations of losartan potassium (Galenova, St-Hyacinthe, QC, Canada) ranging from 0 to 100 µM.
positive cells among the total gated cells, while necrotic cells were quantified by calculating the percentage of mixed with the same volume of chloroform and centrifuged again. The upper solution was recovered and 25 PI-positive cells in the total gated cells.
µl of 3 M sodium citrate was added before the addition Cell Radiolabeling of 1 ml of 100% ethanol. After centrifugation 8 min at 13,000 rpm, the pellets were washed in 70% alcohol Myoblasts cultured in MB-1 for 24 h were radiolabeled by further proliferation for 48 h in MB-1 contain-before another centrifugation. The pellets were then dried before the suspension of the DNA in 100 µl sterile ing 0.25 µCi/ml [methyl-14 C]thymidine (50 mCi/mmol) before their transplantation.
water. Similar aliquots of the DNA solution were mixed with 5 ml of a liquid scintillation counting cocktail Animals (Sigma, Oakville, ON, Canada) and radioactivity was measured in a counter system (Mod. Wallac 1409, All experiments were performed in 2-month-old Rag −/− /mdx mice produced in our animal facilities by Woodbridge, Ontario, Canada). crossing mdx/mdx mice (a DMD model due to a muta-Histological Immunodetection tion leading to dystrophin deficiency) with Rag −/− mice (an immunodeficient mouse that accepts human grafts).
For immunohistochemistry, the TA cross sections were fixed in 4% paraformaldehyde, washed in PBS for The mice were maintained under pathogen-free conditions. All the experiments with mice were conducted in 15 min, and blocked with FBS (10%) in PBS for 1 h.
The following antibodies were used for this study: a accordance with the Laboratory Animal Care and use Ethics Committee of Laval University. mouse anti-human dystrophin mAb (7F7, MRIC Biochemistry Group, Wrexham, UK) (1 h, 1:300); a rab-Losartan Treatment and Cell Transplantation bit polyclonal antibody against pSmad2 (Cell Signal, Danvers, MA) (O/N, 1:1000); a mouse mAb against The myoblast transplantation success was evaluated in mice previously treated or not with oral losartan [0.6 human lamin A/C (Vector laboratory, CA) (30 min, 1: 300) to visualize human nuclei; and a rabbit polyclonal g/L (9,15,37) in drinking water; n = 5] during 15 days. Human myoblasts (5 × 10 5 ) resuspended in 10 µl of antibody against periostin (Abcam, Cambridge, MA) (1 h, 1:250). Depending on the primary antibody, the HBSS were transplanted in both TAs using a glass capillary along 12 transversal axis trajectories. Mice were second reaction was done either with a biotinylated antimouse Ig antibody (Dako, Copenhagen, Denmark) (1:300) euthanatized 1 month after myoblast transplantation.
For muscle regeneration and cell survival experi-followed by streptavidin-Cy3 (Sigma) (1:300), Alexa 488 fluor-conjugated goat anti-rabbit Ig, or anti-mouse ments, mice were treated or not with oral losartan (0.6 g/L in drinking water; n = 5) for 40 days and 5 × 10 5 Ig (Invitrogen Burlington) (1:300) for 1 h at room temperature. Nuclei were stained with DAPI (1:10000) for radiolabeled cells were transplanted in both TAs. 5 min and cryostat sections were mounted using fluoro-Muscle Sampling and Processing mount G (Electron Microscopy Sciences, Hatfield, PA). The dystrophin-positive myofibers were counted in Mice were killed at different posttransplantation times depending on the experiment: at 1 month for experi-12 cryostat sections separated by 150 µm for each of the five muscles of each group. Afterward, the five highest ments to evaluate the myoblast transplantation success and at days 0, 3, and 5 for experiments to evaluate the sections of five TAs from each group were selected and the means + SDs were calculated. early grafted cell survival. Muscles for histological analyses were mounted in embedding medium and snap-Immunodetection of inflammatory cells were performed on muscle cross sections of mice treated 45 days frozen in liquid nitrogen. Serial 12-µm cross sections were obtained in a cryostat at −25°C. Muscles for DNA with oral losartan and transplanted 5 days before the end of the treatment. After fixation with 4% paraformalde-or RNA extraction were placed in microtubes, snapfrozen in liquid nitrogen, and stored at −80°C.
hyde, nonspecific binding sites were blocked by incubating the sections with FBS (10%) in PBS for 1 h. Sections
Quantification of Early Grafted Cell Death
were then incubated with a rabbit anti-mouse Mac-1 polyclonal antibody (Roche Diagnostics, Mississauga, ON, The DNA of the TAs grafted with radiolabeled cells was extracted after 0 and 3 days using the phenol-chlo-Canada) or a biotinylated monoclonal anti-mouse F4-80 (Peninsula Laboratories, San Carlos, CA) for 1 h at room roform method. Briefly, muscles were minced and incubated with 50 µl of proteinase K (10 mg/ml) at 56°C temperature, followed by 30 min with a goat anti-rabbit Ig secondary antibody conjugated with Alexa 546 until the solution became clear. Digested muscles were then mixed with 500 µl of a solution of phenol/chloro-(Invitrogen) and streptavidin-Cy3, respectively. To quantify the labeling fluorescence, we used the Image J. 1.40g form/isoamyl alcohol (25:24:1) and centrifuged 3 min at 13,000 rpm. The upper solution was recovered and (Wayne Rasband, National Institutes of Health, USA).
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Quantitative RT-PCR RESULTS

Losartan Treatment Increased Myoblast Quantitative RT-PCR (Q-RT-PCR) was used to
Growth In Vitro examine the mRNA expression levels of TSP-1, myogenic regulator factors (MRFs) [myogenic differentia-A fluorescence-based assay that correlates with cell tion (MyoD), myogenic factor 5 (Myf5), and myogenin], number was used to determine the effects of losartan inducible nitric oxide synthase (iNOS), and type 1 collaon human myoblast proliferation. Myoblast proliferation gen in the TAs of 45 days oral losartan-treated or was significantly increased after 6 days of treatment untreated mice. The mRNA was extracted using an with 10 and 100 µM losartan (p < 0.05) (Fig. 1A) . RNeasy Plus kit (Qiagen, Mississauga, ON Canada).
Considering that TGF-β1 is a myoblast differentia-The cDNA templates for Q-RT-PCR were synthesized tion inhibitor, we wanted to evaluate in vitro the effect by an inverse transcriptase with 1 µg RNA in superscript of losartan on the myogenic differentiation of human II RNase H-RT reaction (Invitrogen). Q-RT-PCR was myoblasts. After switching confluent myoblasts to a difcarried out in a Light Cycler 480 (Roche) with SYBR ferentiation medium, a losartan treatment during 3 days Green light Cycler Fast Start DNA Master Plus (Roche) increased significantly the number of myotubes immuas a detector. All target gene expressions were normalnostained for MyHC ( Fig. 1B) . Moreover, the fusion ized to glyceraldehyde 3-phosphate dehydrogenase index was significantly increased by 10% with 10 µM (GAPDH) levels. The primer pairs were designed with losartan and by 15% at 100 µM (Fig. 1C) . Thus, the GeneTools logiciels (Biotools Inc., Madrid, Spain) and increased differentiation of human myoblasts by losartan are displayed in Table 1. was dose dependent. not exposed to H 2 O 2 , but reverted apoptosis and necrosis human myoblasts in dystrophic mice, human dystrophin was detected by immunohistochemistry in muscles induced by H 2 O 2 (Fig. 2E) .
Statistical Analysis Losartan Prevented H 2 O 2 -Induced Apoptosis and Necrosis in Myoblasts
transplanted with myoblasts in mice treated or not with losartan during 45 days (Fig. 3A, B ). About 50% more Improved Success of Human Myoblast Transplantation dystrophin-positive myofibers were present in the musin Mice Treated With Losartan cle cross sections of mice treated with losartan (191 ± 40 myofibers per muscle cross section) than in control To investigate the effect of blocking the TGF-β1 signal on the long-term success of the transplantation of mice (126 ± 29) ( Fig. 3C ). Losartan Enhanced the Survival of Engrafted and expressed in regenerating skeletal muscle, was detected by immunoshistochemistry in the sarcolemma Human Myoblasts and endomysium of control mice, but was almost absent To identify the cause of the increased success of in losartan-treated mice (Fig. 5A) . pSmad2, the mammahuman myoblast transplantation in mice treated with lian homolog of the Drosophila mothers against decalosartan, we evaluated the survival of the grafted cells.
pentaplegic (Mad) implicated as downstream effectors We first quantified the human nuclei (identified by human of TGF-β/BMP (bone morphogenetic protein) signaling, lamin A/C immunodetection) present in the cell-grafted was detected in myofiber nuclei of control mice, but not TAs. The number of human nuclei was significantly in mice treated with losartan ( Fig. 5B ). Expression of higher in the TAs of losartan-treated mice compared to TSP-1 mRNA, a potent mediator of angiotensin IIthe controls (Fig. 3D) .
induced TGF-β1 activation via AT-1 was greatly In a second experiment, the early posttransplantation reduced in losartan-treated mice compared with control survival of human myoblasts was evaluated by first mice (Fig. 5C ). radiolabeling them with [ 14 C]thymidine before their transplantation and then quantifying the radiolabel in the Expression of MyoD Family mRNA in Mice Treated cell-grafted muscles at the time of transplantation and 3
With Losartan days later. Approximately 6% of the radiolabel present Q-RT-PCR analyses of Myf5, myogenin, and MyoD in the cell-grafted muscles at time 0 was detected 72 h showed significant increases in the expression of Myf5 posttransplantation in mice untreated with losartan; in and myogenin in mice treated 45 days with losartan contrast, 10% of the radiolabel was still present in losarcompared with control mice (Fig. 6 ). tan-treated mice (Fig. 4) . Thus, there was a significant increase of myoblast survival in mice treated with losartan.
Reduction of Macrophage Infiltration in Losartan-Treated Mice Increased Expression of pSmad2 and Periostin in Losartan-Treated Mice
Immunodetection of Mac-1, a cell surface marker for macrophages but also for bone marrow, spleen, and natu-To evidence a cause-and-effect relationship between losartan treatment and inhibition of TGF-β1 signaling, ral killer cells, granulocytes, and blood monocytes, in the TAs of Rag −/− /mdx mice 5 days after myoblast transplan-we detected periostin, pSmad2, and TSP-1 in skeletal muscles of mice treated or not with losartan during 45 tation demonstrated the presence of inflammatory cells, but no difference was observed between losartan-treated days (Fig. 5) . Periostin, a protein induced by TGF-β1 or untreated mice (Fig. 7A ). However, immunodetection is a potential therapeutic strategy for DMD (4,8). One study showed that losartan, an angiotensin II-type I of F4/80, an antigen present on major subpopulations of resident tissue macrophages (31), in the same muscles receptor blocker usually used for the treatment of hypertension, was well tolerated in mdx mice, and that the demonstrated a lower amount of macrophages in losartan-treated mice (Fig. 7B ). Since iNOS is a main media-administration of this drug for 6-9 months led to muscle improvements such as less fibrosis and increased abso-tor of macrophage cytotoxicity, we wanted to verify whether the decrease in the number of macrophages was lute force (9). Many DMD patients in advanced stages of the disease are currently being treated with losartan accompanied by a decrease in iNOS expression. Using real-time PCR, we observed a decrease of >60% in for the presumptive cardiac benefits of angiotensin IItype I receptor blockers. iNOS expression in the TAs of losartan-treated mice compared with control mice (Fig. 7C ).
Considering the potential benefits of losartan for the treatment of muscle diseases, we decided to test its effects in the context of myoblast transplantation, Dystrophin-Positive Myofibers Size another potential therapeutic tool for DMD (34). Indeed, and Collagen Content our study is the first to demonstrate a potentially benefi-No difference in cross-sectional area of human dyscial role of TGF-β 1 inhibition for human myoblast trophin-positive myofibers was observed between losartransplantation in DMD. We used a Rag −/− /mdx mouse tan-treated and untreated mice (Fig. 8A) . On the other model, which accommodates xenotransplantation, hence hand, the losartan-treated mice had significantly lower human myoblast implantation. concentrations of type I collagen mRNA than untreated Despite the absence of T cells, important producers mice (Fig. 8B) .
of TGF-β, the biological effect of TGF-β was present because this cytokine was secreted by other cells such DISCUSSION as myeloid and dendritic cells (23, 35) . Thus, we observed that mice treated with oral losartan presented TGF-β1 is a member of the TGF-β family and is an endogenous negative regulator of muscle growth. It is 50% more dystrophin-positive myofibers and human nuclei than untreated mice after human myoblast trans-homologous to myostatin and induces several similar effects in muscles, including the inhibition of prolifera-plantation. Considering the other results of the present study, this improvement could be explained by factors tion and differentiation of muscle precursor cells, and stimulation of fibrosis (1,18). The inhibition of TGF-β1 such as an increased early survival, proliferation, and/or differentiation of the transplanted myoblasts, as dis-myoblasts in the improved myoblast transplantation success due to the losartan treatment. In vivo, we observed cussed below.
Some of our experiments support the potential role a 40% improvement of the early survival of the implanted myoblasts in the recipient muscle, measured of the increased early survival of the transplanted by quantifying the radiolabeled cells grafted in losartan-the associated reduction of macrophage recruitment was observed in renal allograft (39) . treated mice. Indeed, one of the problems of a therapy based on myoblast transplantation is the transplanted Other causes of the myoblast transplantation improvement observed are the beneficial effects of losartan on myoblasts acute death within the first 3 days posttransplantation (13, 14, 33) . This phenomenon was attributed the proliferation and/or differentiation of human myoblasts. In our study, the proliferation and differentiation of by some researchers to a cell killing by the inflammatory cells that infiltrate the myoblasts grafts, such as neutro-human myoblasts was significantly increased after inhibition of TGF-β1 in vitro. This positive effect was not phils and monocytes/macrophages. If this is the case, the improvement of the early survival of the implanted observed in C2C12 cells, an immortal mouse myoblast line (24) . Moreover, the estimation of these development myoblasts in losartan-treated mice could be explained by the reduction of the macrophage infiltration and stages was problematic in vivo. MRFs, which are key orchestrators of muscle gene expression, are targeted by iNOS expression evidenced after myoblast transplantation in the present study. Our in vitro experiment showing TGF-β1 signaling. Thus, our results demonstrated the effects of losartan treatment on the mRNA expression a protective effect of losartan against oxidative-induced cell death may further explain the increased early sur-of these genes. MyoD family (i.e., the basic helix-loophelix transcription factors: Myf5, MyoD, and myogenin) vival of the transplanted myoblasts and the increased myogenic differentiation (38) . An attenuation expression plays an essential role as central regulators of myogenesis (26) . Myf5 and MyoD are expressed in myoblasts of molecules involved in macrophage recruitment and
